Ascendis Pharma grants 14,060 employee warrants

Ascendis Pharma A/S granted 14,060 warrants to certain employees on July 14, 2026 under Appendix 1a to its Articles of Association.

Rhea-AI Filing Summary

Ascendis Pharma A/S granted 14,060 warrants to certain employees on July 14, 2026 under Appendix 1a to its Articles of Association. Each warrant entitles the holder to subscribe for one ordinary share at an exercise price of US $265.57 per share.

Subject to earlier vesting upon specified exit events and continued service, 25% of the warrants vest on the first anniversary of the grant date and the remaining 75% vest in equal monthly installments over 36 months thereafter. After this grant, warrants to subscribe for 1,539,503 additional shares remain available for future grants. The report is deemed incorporated by reference into the company’s existing Form S-8 and Form F-3 registration statements.

Filing Explained

Beyond the grant terms, the July 15 6-K states that Ascendis Pharma A/S amended its Articles of Association in connection with the July 14 warrant grant. The filing therefore records employee rights to subscribe for shares under the amended corporate terms, rather than completed share subscriptions.

Key Figures

Employee warrants granted: 14,060 warrants Exercise price: US $265.57 per share Initial vesting portion: 25% +2 more

5 metrics

Employee warrants granted 14,060 warrants Granted to certain employees on July 14, 2026

Exercise price US $265.57 per share Exercise price for each newly granted warrant

Initial vesting portion 25% Vests on the one-year anniversary of the grant date

Remaining vesting period 75% over 36 months Balance vests monthly starting one year after grant

Warrants remaining available 1,539,503 warrants Available for future grant under Articles of Association after this grant

Key Terms

Form 6-K, Articles of Association, warrants, exercise price, +1 more

5 terms

Form 6-K regulatory

"FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER"

A Form 6-K is a report that companies listed in certain countries file to provide important updates, such as financial results, corporate changes, or other significant information, to regulators and investors. It functions like an official company update or news release, helping investors stay informed about developments that could affect their investment decisions.

Articles of Association regulatory

"under the terms of Appendix 1a to the Company’s Articles of Association"

A company's articles of association are its written rulebook that sets how the business is run, how decisions are made, and what rights owners and directors have—covering voting, meetings, appointment and removal of directors, share classes and dividend policies. For investors, these rules matter because they determine how easily control can change, what protections minority owners have, and how corporate actions (like issuing new shares or changing leadership) are approved, much like a home’s bylaws shaping what residents can and cannot do.

warrants financial

"granted an aggregate of 14,060 warrants to certain employees"

Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.

exercise price financial

"has an exercise price equal to US $265.57 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"25% of the Warrants will vest on the one year anniversary of the date of grant"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What new employee warrants did Ascendis Pharma (ASND) approve?

Ascendis Pharma approved 14,060 employee warrants on July 14, 2026. Each warrant allows subscription for one ordinary share at an exercise price of US $265.57, granted under Appendix 1a to the company’s Articles of Association as part of equity-based compensation.

How many warrants did ASND grant and at what exercise price?

Ascendis Pharma (ASND) granted 14,060 warrants with an exercise price of US $265.57 per share. Each warrant gives the right to subscribe for one ordinary share, using the closing market price on the July 14, 2026 grant date as the exercise price.

What is the vesting schedule for Ascendis Pharma’s new warrants (ASND)?

For Ascendis Pharma (ASND), 25% of the warrants vest on the first anniversary of the July 14, 2026 grant. The remaining 75% vest in equal monthly installments over 36 months, subject to continued service and possible earlier vesting on certain exit events.

How many additional warrants remain available for future ASND grants?

After this grant, Ascendis Pharma (ASND) has 1,539,503 warrants remaining available for future grants. These warrants are authorized under the company’s Articles of Association and may be granted later by the board of directors as part of equity incentive programs.

How is this Ascendis Pharma (ASND) warrant grant treated under SEC registrations?

The warrant grant report is deemed incorporated by reference into Ascendis Pharma’s existing Form S-8 and Form F-3 registration statements. This means related disclosures form part of those registered offerings from the filing date, unless later reports supersede them.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/15/2026 - 04:57 PM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of July, 2026

Commission File Number: 001-36815

Ascendis Pharma A/S

(Translation of registrant’s name into English)

Tuborg Boulevard 12

DK-2900 Hellerup

Denmark

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒   Form 40-F ☐

INCORPORATION BY REFERENCE

This report on Form 6-K shall be deemed to be incorporated by reference into the registration statements on Form S-8 (Registration Numbers 333-203040, 333-210810, 333-211512, 333-213412, 333-214843, 333-216883, 333-228576, 333-254101, 333-261550, 333-270088, 333-277519, 333-281916, 333-285322 and 333-293854) and Form F-3 (Registration Numbers 333-209336 and 333-282196) of Ascendis Pharma A/S (the “Company”) (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

Warrant Grants

On July 14, 2026, the Company’s board of directors granted an aggregate of 14,060 warrants to certain employees of the Company (the “Warrants”) under the terms of Appendix 1a to the Company’s Articles of Association. In connection with the grant of these Warrants, the Company amended its Articles of Association to provide for the grant of these Warrants. Each Warrant confers the right to subscribe for one ordinary share of the Company and has an exercise price equal to US $265.57 per share, the closing price of the Company’s ordinary shares as reported on the date of grant. Subject to earlier vesting upon the occurrence of certain exit events, 25% of the Warrants will vest on the one year anniversary of the date of grant and the remaining 75% will vest at a rate of 1/36th per month from one year after the date of grant, subject to continued service.

After giving effect to the grant of the Warrants described above, warrants to subscribe for an additional 1,539,503 shares of the Company remain available for future grant by the Company’s board of directors pursuant to the Company’s Articles of Association. The foregoing description of the material terms of the Warrants is qualified in its entirety by reference to the Company’s Articles of Association, which is included as Exhibit 1.1 hereto and incorporated by reference herein.

Exhibits

Exhibit No.		Description
1.1		Articles of Association.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				Ascendis Pharma A/S
Date: July 15, 2026				By:		/s/ Michael Wolff Jensen
						Michael Wolff Jensen
						Executive Vice President, Chief Legal Officer

Filing Exhibits & Attachments

1 document

Other Documents

• EX-1.1 EX-1.1 499.8 KB